[PS2] Presidential Session 2
【E】

[PS2-3] Neoadjuvant Pembrolizumab/Placebo + Chemo, Followed by Adjuvant Pembrolizumab/Placebo in Early TNBC: Asian Subgroup

^○Masato Takahashi¹, Javier CortÉS², Rebecca Dent³, Lajos Pusztai⁴, Heather Mcarthur⁵, Sherko Kümmel⁶, Carsten Denkert⁷, Yeon Hee Park⁸, Seock-Ah Im⁹, Jin-Hee Ahn¹⁰, Hirofumi Mukai¹¹, Chiun-Sheng Huang¹², Shin-Cheh Chen¹³, Min Hwan Kim¹⁴, Liyi Jia¹⁵, Xin Tong Li¹⁵, Konstantinos Tryfonidis¹⁵, Vassiliki Karantza¹⁵, Hiroji Iwata¹⁶, Peter Schmid¹⁷ (1.Department of Breast Surgery, NHO Hokkaido Cancer Center, 2.Oncology Department, IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, 3.National Cancer Center Singapore, Duke-NUS Medical School, Singapore, 4.Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA, 5.UT Southwestern Medical Center, Dallas, TX, USA, 6.Breast Unit, Kliniken Essen-Mitte Evang, Huyssens-Stiftung, Essen, Germany, 7.Institute of Pathology, Philipps University Marburg, Marburg, Germany, 8.Hematology-Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 9.Seoul National University Hospital, Cancer Research Institute, Seoul National University, Seoul, Republic of Korea, 10.Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, 11.National Cancer Center Hospital East, Kashiwa-shi, Japan, 12.National Taiwan University Hospital, Taipei, Taiwan, 13.Chang Gung University Medical College, Taipei, Taiwan, 14.Yonsei University College of Medicine, Seoul, South Korea, 15.Merck & Co., Inc., Kenilworth, NJ, USA, 16.Aichi Cancer Center Hospital, Nagoya, Japan, 17.Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK)